$236.90 Million in Sales Expected for Prestige Consumer Healthcare Inc (PBH) This Quarter

Share on StockTwits

Equities research analysts forecast that Prestige Consumer Healthcare Inc (NYSE:PBH) will announce sales of $236.90 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Prestige Consumer Healthcare’s earnings, with the highest sales estimate coming in at $239.10 million and the lowest estimate coming in at $234.90 million. Prestige Consumer Healthcare posted sales of $255.97 million in the same quarter last year, which would suggest a negative year over year growth rate of 7.5%. The company is expected to announce its next earnings report before the market opens on Thursday, May 9th.

On average, analysts expect that Prestige Consumer Healthcare will report full-year sales of $971.65 million for the current fiscal year, with estimates ranging from $969.70 million to $973.90 million. For the next year, analysts expect that the business will report sales of $956.18 million, with estimates ranging from $950.00 million to $959.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 7th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.02. The business had revenue of $241.40 million for the quarter, compared to analyst estimates of $241.40 million. Prestige Consumer Healthcare had a return on equity of 11.85% and a net margin of 6.44%. The company’s quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 earnings per share.

PBH has been the subject of several recent research reports. ValuEngine lowered shares of Prestige Consumer Healthcare from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 10th. Desjardins downgraded Prestige Consumer Healthcare to a “hold” rating and set a $88.00 price objective on the stock. in a report on Wednesday, February 13th. Zacks Investment Research upgraded Prestige Consumer Healthcare from a “sell” rating to a “hold” rating in a report on Tuesday. Raymond James downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating and set a $28.40 price objective on the stock. in a report on Tuesday, January 15th. Finally, Royal Bank of Canada restated a “buy” rating and set a $97.00 price objective on shares of Prestige Consumer Healthcare in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $54.07.

NYSE:PBH traded up $0.24 on Friday, hitting $29.65. The stock had a trading volume of 3,139 shares, compared to its average volume of 546,381. The firm has a market cap of $1.52 billion, a P/E ratio of 11.48, a PEG ratio of 1.66 and a beta of 0.96. The company has a debt-to-equity ratio of 1.49, a quick ratio of 1.34 and a current ratio of 2.28. Prestige Consumer Healthcare has a 52 week low of $26.25 and a 52 week high of $41.76.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $18,328,000. Dimensional Fund Advisors LP boosted its holdings in Prestige Consumer Healthcare by 11.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,049,957 shares of the company’s stock worth $125,062,000 after buying an additional 420,265 shares during the period. LSV Asset Management boosted its holdings in Prestige Consumer Healthcare by 183.1% in the 4th quarter. LSV Asset Management now owns 491,784 shares of the company’s stock worth $15,186,000 after buying an additional 318,043 shares during the period. JPMorgan Chase & Co. boosted its holdings in Prestige Consumer Healthcare by 9.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,030,923 shares of the company’s stock worth $114,842,000 after buying an additional 255,561 shares during the period. Finally, BlackRock Inc. boosted its holdings in Prestige Consumer Healthcare by 4.0% in the 4th quarter. BlackRock Inc. now owns 6,457,359 shares of the company’s stock worth $199,402,000 after buying an additional 248,243 shares during the period.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

Recommended Story: What is Compound Interest?

Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.